Tirzepatide: Understanding GIP and GLP-1

Tirzepatide is a prescription medicine that acts on two hormone receptors involved in blood glucose regulation and appetite: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).

It has been extensively studied for type 2 diabetes and weight management. In the European Union, the authorised medicine Mounjaro contains tirzepatide and is available by prescription for specific medical uses.

What Is Tirzepatide?

Tirzepatide is a long-acting GIP and GLP-1 receptor agonist. These hormones naturally play important roles in regulating blood sugar, appetite and food intake.

Unlike medicines that target only the GLP-1 receptor, this treatment activates both GIP and GLP-1 receptors. This dual mechanism is an important feature of its pharmacological activity.

How Does It Work?

The medication works by activating GIP and GLP-1 receptors in the body. These pathways are involved in several processes related to glucose and appetite regulation.

Its effects can include:

• Supporting glucose-dependent insulin secretion
• Helping regulate blood glucose
• Reducing appetite and food intake
• Increasing feelings of fullness
• Influencing energy metabolism

The effects can vary between individuals, and treatment should be determined according to a person’s medical circumstances.

Research Into Type 2 Diabetes

The active ingredient has been studied extensively in people with type 2 diabetes.

Clinical research has examined outcomes such as:

• HbA1c and blood glucose levels
• Body weight
• Insulin response
• Cardiometabolic measurements
• Long-term treatment outcomes

In the EU, Mounjaro is authorised for specific type 2 diabetes indications alongside diet and exercise. Treatment decisions should be made with a qualified healthcare professional.

Research Into Weight Management

Clinical studies have also investigated this medicine in people living with overweight or obesity.

Research suggests that activation of GIP and GLP-1 pathways can influence appetite and energy intake. Studies have reported reductions in body weight in appropriately selected participants receiving treatment.

However, clinical trial results do not guarantee the same outcome for every individual. Weight management should be approached as part of an overall medical plan.

Possible Side Effects

As with any prescription medicine, adverse effects are possible.

Commonly reported gastrointestinal effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort or pain

The likelihood and severity of side effects can differ between individuals. Always consult the current official product information and a healthcare professional for complete safety information.

Important Information Before Treatment

This is a prescription medicine and should be used under appropriate medical supervision.

A healthcare professional can determine whether treatment is appropriate by considering factors such as medical history, existing medicines and other individual circumstances.

Do not use information from an online page as a substitute for professional medical advice.

Understanding Medical Research

There is a difference between evidence from clinical research and claims made online.

When researching this treatment, consider information from:

• Recognised medical authorities
• Regulatory agencies
• Published clinical research
• Official product information
• Qualified healthcare professionals

Be cautious of websites or social-media posts making guaranteed claims about weight loss, diabetes treatment or other health outcomes.

Frequently Asked Questions

What is tirzepatide?

It is a long-acting medicine that activates both GIP and GLP-1 receptors and is used in authorised prescription medicines for specific medical conditions.

Is it a GLP-1 medicine?

It activates the GLP-1 receptor but also acts on the GIP receptor. It is therefore commonly described as a dual GIP/GLP-1 receptor agonist.

What is it used for?

In the European Union, Mounjaro is authorised for specific type 2 diabetes and weight-management indications. The appropriate use depends on the individual and should be determined by a healthcare professional.

How does it affect appetite?

Activation of GIP and GLP-1 pathways can influence appetite and energy intake. Clinical research has reported reduced food intake and increased feelings of fullness in people receiving treatment.

Can it cause side effects?

Yes. Gastrointestinal effects such as nausea, vomiting, diarrhoea and constipation are among the commonly reported adverse effects.

Medical Disclaimer

This page is provided for general educational purposes only. Tirzepatide is a prescription medicine. The information provided here is not medical advice, a diagnosis or a recommendation for treatment. Always consult a qualified healthcare professional before starting, changing or stopping any medication.